Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results
January 31 2019 - 4:00PM
Business Wire
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi
therapeutics company, announced today that it will report financial
results for the fourth quarter and year ending December 31, 2018 on
Thursday, February 7, 2019, after the U.S. financial markets
close.
Management will provide an update on the Company and discuss
fourth quarter and year-end 2018 results as well as expectations
for the future via conference call on Thursday, February 7, 2019 at
4:30 pm ET. To access the call, please dial 800-667-5617 (domestic)
or 334-323-0509 (international) five minutes prior to the start
time and refer to conference ID 4263166. A replay of the call will
be available beginning at 7:30 pm ET on the day of the call. To
access the replay, please dial 888-203-1112 (domestic) or
719-457-0820 (international) and refer to conference ID
4263166.
A live audio webcast of the call will be available on the
Investors section of the Company’s website, www.alnylam.com. An
archived webcast will be available on the Alnylam website
approximately two hours after the event.
About Alnylam PharmaceuticalsAlnylam (Nasdaq: ALNY) is
leading the translation of RNA interference (RNAi) into a new class
of innovative medicines with the potential to improve the lives of
people afflicted with rare genetic, cardio-metabolic, hepatic
infectious, and central nervous system (CNS)/ocular diseases. Based
on Nobel Prize-winning science, RNAi therapeutics represent a
powerful, clinically validated approach for the treatment of a wide
range of severe and debilitating diseases. Founded in 2002, Alnylam
is delivering on a bold vision to turn scientific possibility into
reality, with a robust discovery platform. ONPATTRO® (patisiran)
lipid complex injection, available in the U.S. for the treatment of
the polyneuropathy of hereditary transthyretin-mediated (hATTR)
amyloidosis in adults, is Alnylam’s first U.S. FDA-approved RNAi
therapeutic. In the EU, ONPATTRO is approved for the treatment of
hATTR amyloidosis in adults with stage 1 or stage 2 polyneuropathy.
Alnylam has a deep pipeline of investigational medicines, including
three product candidates that are in late-stage development.
Looking forward, Alnylam will continue to execute on its “Alnylam
2020” strategy of building a multi-product, commercial-stage
biopharmaceutical company with a sustainable pipeline of RNAi-based
medicines to address the needs of patients who have limited or
inadequate treatment options. Alnylam employs over 1,000 people
worldwide and is headquartered in Cambridge, MA. For more
information about our people, science and pipeline, please visit
www.alnylam.com and engage with us on Twitter at @Alnylam or on
LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190131005646/en/
Alnylam Pharmaceuticals, Inc.Christine Regan
Lindenboom(Investors and Media)617-682-4340
Josh Brodsky(Investors)617-551-8276
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Sep 2023 to Sep 2024